2025年,在集采深化、国内市场承压、国际竞争加剧与创新驱动并行的多重考验下,第三季度财报成为观测行业脉动与风向的关键窗口。截至目前,国内超130家医疗器械上市企业已披露2025年三季报,营业收入中位数达2.51亿元,但归母净利润中位数仅0.21亿元。历经调整期的国内医疗器械市场,是否已迎来众人期盼的关键“拐点”?01 业绩分化:高值耗材与设备回暖,IVD领域仍陷“寒冬”众成数科数据显示,...
Source Link2025年,在集采深化、国内市场承压、国际竞争加剧与创新驱动并行的多重考验下,第三季度财报成为观测行业脉动与风向的关键窗口。截至目前,国内超130家医疗器械上市企业已披露2025年三季报,营业收入中位数达2.51亿元,但归母净利润中位数仅0.21亿元。历经调整期的国内医疗器械市场,是否已迎来众人期盼的关键“拐点”?01 业绩分化:高值耗材与设备回暖,IVD领域仍陷“寒冬”众成数科数据显示,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.